The report highlights Daiichi Sankyo's commitment to sustainable improvement of corporate value by integrating business activities with responsible corporate activities. Key highlights include the launch of edoxaban, a novel anticoagulant, in Japan, the U.S., and Europe; the divestment of Ranbaxy Laboratories Ltd., a former Indian subsidiary; and the expansion of the company's R&D pipeline in oncology and pain management. The report also details the company's efforts in responsible corporate activities, including environmental management, social contribution, and communication with stakeholders.
Issuing Company Daiichi Sankyo Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 6.1 MB
No. of Pages 49 pages
Reporting periodApril 1, 2014-March 31, 2015
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue